Health ❯ Obesity

Medications

GLP-1 Drugs GLP-1 Pharmaceuticals GLP-1 Agonists Anti-Obesity Drugs Weight Management GLP-1 Receptor Agonists Wegovy Semaglutide Tirzepatida

Novo Nordisk Sees Up to 13% Drop in 2026 Profit and Sales After 'Unprecedented' U.S. Price Squeeze

Shares fell as much as 20% on the outlook.

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

Argentina Launches Lilly’s Mounjaro for Obesity and Diabetes After ANMAT Approval

White House Strikes Deals With Lilly and Novo to Cut GLP-1 Prices, Widen Medicare Access

Pfizer Sues Metsera and Novo Nordisk to Enforce Deal After Novo’s Higher Bid

EMA Flags Very Rare Vision-Loss Risk for Ozempic and Wegovy

Novo Nordisk Launches Wegovy in France Without Reimbursement

Compounded Weight Loss Drugs Raise Safety and Ethical Concerns